Skip to main content

Table 3 Univariate and multivariate Cox-regression analysis of clinical factors associated with the occurrence of KDIGO 3 acute kidney injury

From: Comparison of colistin-induced nephrotoxicity between two different formulations of colistin in critically ill patients: a retrospective cohort study

  Univariate analysis Multivariate analysis
OR (95% CI) P-value aOR (95% CI)a P-value
Age 0.99 (0.97–1.01) 0.236 0.99 (0.96–1.02) 0.463
Sex  
Female 1.00 1.00
Male 0.72 (0.38–1.36) 0.312 0.70 (0.34–1.46) 0.346
Baseline eGFR < 30 1.65 (0.69–3.91) 0.260 1.41 (0.48–4.14) 0.536
Diabetes 0.93 (0.47–1.82) 0.824 1.16 (0.56–2.41) 0.681
APACHII ≥ 25 0.64 (0.34–1.20) 0.162 0.53 (0.24–1.17) 0.118
Albumin ≤ 3 g/dL 0.81 (0.42–1.54) 0.522 0.66 (0.34–1.28) 0.221
CRAB 0.61 (0.29–1.29) 0.197 0.53 (0.24–1.17) 0.118
Aminoglycoside 1.01 (0.40–2.58) 0.982 0.99 (0.34–2.86) 0.979
Vancomycin 1.99 (0.92–4.3) 0.082 1.59 (0.65–3.89) 0.310
Intravenous contrast 1.07 (0.51–2.23) 0.865 0.89 (0.37–2.12) 0.785
Septic shockb 2.79 (1.51–5.16) 0.001 2.17 (1.10–4.26) 0.025
Daily colistin > 10 MIU 1.75 (0.94–3.26) 0.077 1.32 (0.61–2.83) 0.482
Colistin treatment duration 0.98 (0.92–1.03) 0.411 0.99 (0.93–1.04) 0.617
Inappropriate colistin dosage 2.29 (1.09–4.80) 0.028 2.52 (1.00–6.33) 0.049
Colistin formulation  
Locolin® 1.00 1.00
Colimycin® 0.42 (0.22–0.82) 0.011 0.37 (0.18–0.77) 0.008
  1. aAdjusted odds ratio (aOR) and 95%CI were derived from cox regression analysis
  2. bPresent on the day of sample collection